ClinConnect ClinConnect Logo
Search / Trial NCT04692259

May the Risk of PHLF be Predicted With Preoperative Liver Gadoxetate MRI

Launched by UNIVERSITY HOSPITAL, LINKOEPING · Dec 30, 2020

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Mri Postoperative Liver Failure Gadolinium Liver Resection

ClinConnect Summary

This clinical trial is studying how a specific type of MRI, called Gadoxetate MRI, can help predict the risk of a serious complication called post hepatectomy liver failure (PHLF) after liver surgery. PHLF can happen when the liver doesn’t recover properly after a part of it is removed, which can lead to serious health issues. The researchers want to see if this MRI can provide better information about how well the liver is functioning before surgery, making it easier for doctors to assess which patients might be at higher risk for complications.

To be eligible for this trial, participants need to be adults aged 18 or older who have had a Gadoxetate MRI (also known as Primovist MRI) within a certain timeframe before their liver surgery. This includes patients with cirrhosis (a liver condition) or those who have had specific types of liver volume treatments. Participants will be asked to share their medical information and the results of their MRIs to help researchers understand the relationship between liver function and the risk of PHLF. It’s important to know that this study is currently recruiting participants and aims to improve safety and outcomes for future liver surgery patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients who have had a Primovist MRI within 8 weeks before hemihepatectomy or extended hemi-hepatectomy +/- bile duct anastomosis independent of diagnosis.
  • 2. Patients with cirrhosis who have had a Primovist MRI within 8 weeks before resection of more than one liver segment
  • 3. Patients who had liver volume augmentation with a pre-operative Primovist MRI less than 2 weeks before resection
  • 4. Patients who have had a Primovist MRI within 6 weeks be-fore any liver resection where PHLF or death within 90 days occurred.
  • -
  • Exclusion Criteria:
  • 1. \<18 years of age
  • 2. Resection was not performed -

About University Hospital, Linkoeping

The University Hospital in Linköping is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pivotal institution within the region, it integrates cutting-edge medical practices with academic excellence, facilitating a collaborative environment for healthcare professionals and researchers. The hospital actively participates in a wide range of clinical trials across various medical disciplines, aiming to enhance patient outcomes and contribute to the global body of medical knowledge. With a focus on ethical standards and patient safety, the University Hospital in Linköping is dedicated to pioneering solutions that address pressing health challenges.

Locations

Göteborg, , Sweden

Uppsala, , Sweden

Oslo, , Norway

Stockholm, , Sweden

Copenhagen, , Denmark

Helsinki, , Finland

Linköping, Ostergotland, Sweden

Stockholm, Södermanland, Sweden

Patients applied

0 patients applied

Trial Officials

Per Sandström, Prof

Principal Investigator

Academic study

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials